Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: Insights from the TACTICS TIMI-18 trial

Journal of the American College of Cardiology

Volumn 41, Issue 4 SUPPL. 4, 2003, Pages S43-S48

  Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; TIROFIBAN; TROPONIN;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CORONARY STENT; DEATH; DIABETES MELLITUS; DRUG COST; EXERCISE TEST; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0037454082     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0735-1097(02)03018-8     Document Type: Review

References (44)

1. The Platelet Receptor Inhibition for Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-505.
2. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study [published erratum appears in Lancet 1997;350:744]. Lancet 1997;349:1429-35.
3. The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
4. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
5. Topol EJ, Byzova TV, Plow ER. Platelet GP IIb-IIIa blockers. Lancet 1999;353:227-31.
6. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-35.
7. Barr E, Thornton AR, Sax FL, Snapinn SM, Theroux P. Benefit of tirofiban + heparin therapy in unstable angina/non-Q-wave myocardial infarction patients is observed regardless of interventional treatment. Circulation 1998;98 Suppl I:I504.
8. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999;100:2045-8.
9. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24.
10. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, et al. Attainment and maintenance of platelet inhibition by standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 1999;100:1977-82.
11. Tardiff BE, Jennings LK, Harrington RA, et al. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation 2001; 104:399-405.
12. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106:1893-900.
13. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-9.
14. Heeschen C, Hamm CW, Goldmann B, et al, Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757-62.
15. Newby LK, Ohman EM, Christenson RH, et al, Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the PARAGON-B troponin T substudy. Circulation 2001;103:2891-6.
16. Januzzi JL, Chai CU, Sabatine MS, Jang IK, Elevation in serum troponin I predicts the benefit of tirofiban. J Thromb Thrombolysis 2001;11:211-5.
17. Theroux P, Ghannam A, Nasmith J, Barr E, Snapinn SM, Sax FL. Improved cardiac outcomes in diabetic unstable angina/non-Q-wave myocardial infarction patients treated with tirofiban and heparin. Circulation 1998;98 Suppl I:I359.
18. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767-71.
19. Klootwijk P, Meij S, Melkert R, Lenderink T, Simoons ML. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation 1998;98:1358-64.
20. Alexander JH, Harrington RA, Tuttle RH, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1999;83:1147-51.
21. Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST-elevation acute coronary syndromes: application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002;23:223-9.
22. Heeschen C, van den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 1999;100:1509-14.
23. Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 Substudy. Circulation 2002;106:202-7.
24. van den Brand M, Laarman GJ, Steg PG, et al. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. Eur Heart J 1999;20: 1572-8.
25. Zhao X-Q, Theroux P, Snapinn SM, Sax FL, for the PRISM-PLUS Investigators. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms). Circulation 1999;100:1609-15.
26. Gibson M, Murphy SA, Weisberg S, et al. Early initiation of tirofiban therapy before percutaneous coronary intervention is associated with improved flow and tissue level perfusion: a TACTICS-TIMI 18 substudy. Circulation 2001;104 Suppl II:II548-9.
27. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Circulation 1994;89:1545-56.
28. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
29. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-50.
30. McCullough PA, O'Neill WW, Graham M, et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the Medicine versus Angiography in Thrombolytic Exclusion (MATE) trial. J Am Coll Cardiol 1998;32:596-605.
31. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative strategy. N Engl J Med 1998;338:1785-92.
32. FRagmin and fast revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:708-15.
33. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during InStability in Coronary artery disease. Lancet 2000;356:9-16.
34. Mehta S, Yusuf S, Hunt D, Natarajan M. Invasive versus conservative management of unstable angina and non-Q-wave infarction: a meta-analysis. Circulation 1999;100 Suppl I:I775.
35. Sabatine MS, Cannon CP, Murphy SA, DiBattiste PM, Demopoulos LA, Braunwald E. Implications of upstream GP IIb/IIIa inhibition and stenting in the invasive management of UA/NSTEMI: a comparison of TIMI IIIB and TACTICS-TIMI 18. Circulation 2001;104 Suppl II:II549.
36. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponin I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST-segment elevation myocardial infarction: results from a randomized trial. JAMA 2001; 286:2405-12.
37. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events fin unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100: 1593-601.
38. The TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary artery disease (TIME): a randomised trial. Lancet 2001;358:951-7.
39. Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation 1997;96:748-55.
40. Spacek R, Widimsky P, Straka Z, et al. Value of first day angiography/angioplasty in evolving non-ST-segment elevation myocardial infarction: an open multicenter randomized trial. The VINO Study. Eur Heart J 2002;23:191-4.
41. Fox KA, Poole-Wilson PA, Henderson RA, et al. Randomized Intervention Trial of unstable Angina Investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002;360:743-51.
42. Grech ED, Sutton AG, Campbell PG, et al. Reappraising the role of immediate intervention following thrombolytic recanalization in acute myocardial infarction. Am J Cardiol 2000;86:400-5.
43. Solomon DH, Stone PH, Glynn RJ, et al. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. J Am Coll Cardiol 2001;38:969-76.
44. Michalis LK, Stroumbis CS, Pappas K, et al. Treatment of refractory unstable angina in geographically isolated areas without cardiac surgery. Invasive versus conservative strategy (TRUCS study). Eur Heart J 2000;21:1954-9.